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SUMMARY
Many countries are currently studying the possibility of mass vaccination against varicella. The
objective of this study was to provide a comprehensive picture of the pre-vaccine epidemiology
of the varicella zoster virus (VZV) to aid in the design of immunization programs and to
adequately measure the impact of vaccination. Population-based data including physician visit
claims, sentinel surveillance and hospitalization data from Canada and the United Kingdom
were analysed. The key epidemiological characteristics of varicella and zoster (age specific
consultation rates, seasonality, force of infection, hospitalization rates and inpatient days) were
compared. Results show that the overall epidemiology of varicella and zoster is remarkably
similar between the two countries. The major difference being that, contrary to Canada, the
epidemiology of varicella seems to be changing in the United Kingdom with an important
decrease in the average age at infection that coincides with a significant increase in children
attending preschool. Furthermore, differences exist in the seasonality between the United
Kingdom and Canada, which seem to be primarily due to the school calendar. These results
illustrate that school and preschool contact patterns play an important role in the dynamics of
varicella. Finally, our results provide baseline estimates of varicella and zoster incidence and
morbidity for VZV vaccine effectiveness and cost-effectiveness studies.
INTRODUCTION
Varicella zoster virus (VZV) produces two distinct
clinical syndromes: varicella and zoster. Varicella or
chickenpox is the primary manifestation of VZV
infection. In temperate climates in the absence of
vaccine, the lifetime risk for varicella is over 95% [1].
Over 90% or more of cases occur during the first 15
years of life and the burden of illness is predominantly
borne by otherwise healthy children [2–4]. Following
* Author for correspondence.
primary infection the virus becomes latent in dorsal
root ganglia and may reactivate decades later to cause
zoster, also known as shingles, in a significant
proportion of the population [5, 6]. The events leading
to reactivation are not clearly understood although
decreased cell-mediated immunity is thought to play a
major role [6]. The overwhelming burden of illness
due to zoster is suffered by the elderly due not only to
the increased incidence of reactivation after age 50 but
also the increased frequency of post-herpetic neuralgia
[6, 7].
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A live attenuated VZV vaccine was developed in
1975 [8]. The vaccine has been licensed in many
countries and in 1995 was introduced into the routine
immunization schedule for healthy children in the
United States [9]. Many other countries are currently
studying the possibility of mass vaccination [10–15].
However, some important questions remain which
limit the widespread acceptability of the vaccine in
these countries. The main concern is that, by reducing
the incidence of varicella, vaccination would cause an
increase in the average age at infection, which could
lead to an overall increase in morbidity [16]. Other
concerns are the high number of breakthrough
infections in vaccinees and the effect of vaccination on
the incidence of zoster [17, 18].
To evaluate the overall impact and cost-effective-
ness of varicella vaccination, it is necessary to
understand the pre-vaccine epidemiology of both
primary and reactivated VZV infection. This paper
analyses surveillance and hospitalization data from
the United Kingdom and Canada to investigate the
following key epidemiological characteristics of var-
icella and zoster in developed countries : (1) age
distribution; (2) annual incidence; (3) seasonal
patterns ; (4) the age-specific force of varicella in-
fection; and (5) rate and duration of hospitalization.
METHODS
Data
Canada
Population-based data were obtained using annual
physician billing claims and hospital separations from
the province of Manitoba during 1979–97. During
this interval the population of Manitoba varied from
1–08 to 1–16 million with approximately 16000 births
per year. The province is generally representative of
Canada in indicators of health status, socio-economic
status and provincial expenditures on health care [19,
20]. The methodology for abstracting health claims
data in Manitoba has previously been validated and
documented [21]. The physician claims files include an
encrypted personal health identification number
(PHIN), date of service, physician specialty, clinical
setting and a single 3-digit International Classification
of Disease code (ICD-9) indicating the reason for the
claim. For zoster, only the first claim for an individual
was included regardless of the time interval between
first and second or more claims in order to measure
incidence.
The hospital separations file covers both acute and
long term stay hospitals, and includes up to 16 five
digit ICD-9 codes, the PHIN, the admission and
discharge dates, urgency of admission, surgical pro-
cedure codes and status at discharge. Complete data
are available for all fiscal years from 1979 through to
the present, which for this study included fiscal year
1997.
United Kingdom
For the United Kingdom, information on the age-
specific consultation rate for varicella and zoster is
available through the Royal College of General
Practitioners (RCGP), which instituted a sentinel
surveillance programme in 1967 using a representative
sample of the practitioners throughout England and
Wales [22]. The diagnosis, age and sex of each patient
with a new illness are reported weekly. Additional age-
specific consultation rates for varicella and zoster are
available from the National Survey of Morbidity in
General Practice (MSGP4) database, which was
derived from a survey of 60 English and Welsh general
practices in 1991–2 [23]. The study covered a 1%
sample of the population of England and Wales
(502493 patients, 468042 person-years at risk). The
database includes the number of persons consulting
by age and ICD-9 diagnosis.
Hospitalization data for the UK was extracted from
Hospitalization Episode Statistics (HES database) for
1995}6, which covers every inpatient admission in
England during this period (approximately 49000000
person-years at risk). Data obtained from the HES
database included the dates of admission, discharge
and birth, and discharge diagnosis coded by ICD-10.
An identical algorithm was used to identify varicella
and zoster hospitalizations for both the Canadian and
UK hospital datasets. The specific algorithm relies on
the discharge diagnosis based on the ICD-9 and-10
codes for varicella (052 and B0l respectively) and
zoster (053 and B02). All claims with either 052, B0l,
053 or B02 were included. For both Manitoba and
England all hospital separations with a varicella or
zoster diagnostic code in one or more of the first three
positions were considered to be admissions due to a
VZV unless major trauma was listed as the principal
diagnostic code (e.g. fracture, burns, etc). Finally, all
admissions with a length of stay of 0 days were
assumed to represent outpatient procedures or can-
celled elective admissions and were thus excluded
from analysis.
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Force of infection of varicella
The force of infection is the instantaneous incidence
rate of infection amongst susceptibles. It was esti-
mated, here, from physician consultation data
(Manitoba billings, RCGP and MSGP4 data [22, 23].
To estimate the force of infection from physician
consultation data, consultation rates were adjusted
given that physicians do not see all children with
chickenpox. The proportion of children with varicella
seen by a physician in Manitoba for the 0–6 age
groups was estimated by dividing, for each age, the
rate of consultation of the 1990 Manitoba birth-
cohort by the incidence rate from the Manitoba
school survey [24] performed on the same cohort. The
estimated percent of children with varicella seen by a
physician for each year of age for 0–6 years were 57,
48, 32, 21, 22, 27 and 30%. These estimates fit the
reported data for frequency of physician visits for
children with chickenpox [25–28]. Similar estimates
for those over 7 years of age were derived from the
literature assuming that all individuals contract
varicella during their lifetime [1, 29]. The proportion
for 7–10, 11–14, 15–24, 25–34, 35–54 and 55› age
groups respectively was 30, 37, 65, 90, 95 and 100%.
For physician consultation data, the force of infection
was calculated by using Farrington’s [30] functional
form to generate an expected proportion of indi-
viduals of age X who would have been exposed to
the virus. The function is fitted to the observed
age-specific proportion of individuals with history
of infection using maximum likelihood methods.
Lifetime risk of zoster
The lifetime risk of at least one reactivation of VZV
was estimated by calculating the cumulative incidence
of zoster and assuming life expectancy is 78 years
(average life expectancy at birth in Manitoba and
England during the 1990s (www.statcan.ca and
www.doh.gov.uk). The cumulative incidence was
calculated from the average age-specific rates of
incident zoster consultation in Manitoba and England
and Wales between 1990 and 1997.
RESULTS
Varicella
Age dependent annual consultation rates
Since 1979 the proportion of all varicella consultations
among children under 15 years has remained roughly
Table 1. Aerage consultation rates (per 100000
population-year) for aricella in Canada and the
United Kingdom, 1979–97*
Age group
Varicella Herpes zoster
Canada UK Canada UK
0–4 2345 3414 64 76
5–14 1306 1696 121 179
15–44 115 249 192 210
45–64 15 30 423 470
65› 12 14 812 771
* Rates are per 100000 population-year. Population esti-
mates were taken from the Office of National Statistics for
England and Statistics Canada for Manitoba.
stable at around 85% for both Canada and the
United Kingdom. The average consultation rates for
varicella in Canada and the United Kingdom between
1979 and 1997 are presented in Table 1.
There was a remarkable increase in varicella
consultation rates in children under 5 in the United
Kingdom. In 1979–83 and 1994–8 consultation rates
in the UK increased by 135% to 4467 consultations
per 100000 person-year in children under 5 years (Fig.
1b). In addition, consultations in older children (5–14
years) decreased by 53% to 1052 consultations per
100000 person-year over the same time period.
Canadian data show an upward shift in varicella
consultation rates for all age groups, with a pro-
portionally higher increase in adults (175% increase
to 162 consultations per 100000 person-year in
1979–83 and 1993–7, Fig. 1a).
Seasonality
Varicella cases increase throughout the school year
(September to June) for both the United Kingdom
and Canada then fall sharply during summer vacation
(June to September) (Fig. 2a, d). Interestingly,
Canada has one peak (June, Fig. 2a) while the United
Kingdom has two peaks of varicella incidence (middle
of March and June, Fig. 2d). The seasonal pattern
seen in the 0–14 age group becomes less pronounced
with increasing age groups (Fig. 2b, c, e, f ).
Force of infection
Estimated values for the force of infection differed
between Canada and the United Kingdom among
children under 12 years (Table 2). For children under
1, the United Kingdom force of infections was 0–11
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Fig. 1. Annual varicella consultation rate. Annual age-specific varicella consultation rate in (a) Manitoba from 1979–97, and
(b) England and Wales from 1967–98. The X-axes in the main panels are aligned.
infections per susceptible-year, compared to 0–05 in
Canada. Conversely among children of 5–11 years,
there was an estimated 0–20 infections per susceptible-
year, compared to 0–15 in the United Kingdom.
Hospitalization and inpatient days
Hospitalization per 100000 population and pro-
portion of hospitalizations per case of varicella are
strikingly similar between the United Kingdom and
Canada (Table 3). The proportion admitted to
hospital per varicella case is high in children under 2
years of age (E 2% of cases), falls to approximately
0–50% in 2–18 year-olds then increases significantly
throughout adult life to 6% in those over 65 years.
The average number of inpatient days per
hospitalized case of varicella also increases with age
from 4 days in children to 17 days in adults over 65
years. Although the shape of the relationship between
average inpatient stay and age is similar between
Canada and the United Kingdom, Canada has
systematically a higher number of days in hospital
(average of 2 days more per hospitalization, Table 3).
The number of hospitalizations and average num-
ber of inpatient days per hospitalized case of varicella
has not significantly changed in Canada since 1979.
However, since 1979, the overall number of
hospitalizations has increased in the United Kingdom
[1] while overall rates of infection have remained
relatively stable. The shift of varicella infection in the
United Kingdom from the 5–15 age group, which
have the lowest severity, to children under 5 and
adults both of whom have higher severity (Table 3)
may explain the overall increase in hospitalization.
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Fig. 2. Varicella seasonality. Average monthly rate of consultations for varicella in Manitoba between 1979 and 1997 for age
groups (a) 0–14 years, (b) 15–44 years and (c) over 45 years. Average weekly rates of varicella consultation in England and
Wales between 1979 and 1997 for ages. (d) 0–14 years, (e) 15–44 years and (f) over 45 years.
Zoster
Age dependent annual consultation rates
The estimated average lifetime risk of at least one
VZV reactivation in Canada and the United Kingdom
between 1990 and 1997 was 28 and 30% respectively.
The age distribution of zoster is similar between
Canada and the United Kingdom. The proportion of
zoster consultations in each age group has remained
relatively constant through time with over 60% of
consultations occurring in individuals older than 45
years of age and less than 9% in children under 15
years. However, in the United Kingdom, a slight
increase of zoster consultations can be observed in
individuals over 65 years of age (from 27% in 1979 to
39% in 1998). The average consultation rates for
zoster in Canada and the United Kingdom between
1979 and 1997 are presented in Table 1. Again, the
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Table 2. Estimated aricella force of infection
(infections per susceptible-year) by age group
Age group Canada* UK
0–1 0–05 0–11
2–4 0–16 0–18
5–11 0–20 0–15
12–18 0–10 0–09
19–24 0–09 0–09
25–44 0–08 0–08
45–64 0–05 0–07
65› 0–04 0–07
* Manitoba medical billings data, 1990–3.
 RCGP and MSGP4 data, 1991–2.
average consultation rates are generally higher in the
United Kingdom than in Canada.
Since the beginning of the 1980s, the overall zoster
consultation rate has been slowly increasing in Canada
and the United Kingdom. Between 1979 and 1997 the
overall zoster consultation rate has risen from 258 to
348 and 315 to 382 per 100000 years in Canada and
the United Kingdom respectively.
The sharp fall of UK varicella consultation rates in
5–14 year olds since the early 1980s (Fig. 1b) coincides
with an increase in zoster in the same age group (53%
increase to 233 zoster consultations per 100000
person-year between 1983 and 1998). Temporal
correlation between varicella and zoster for the 5–14
age group was significant between 1983 and 1998
(rflfi0–72). No temporal correlation was identified
between the other age groups.
Seasonality
Zoster does not seem to possess a seasonal pattern.
The weekly and monthly average age-specific rates of
zoster consultation display no identifiable periodicity
in the United Kingdom and Canada. Furthermore,
zoster does not seem to be correlated to the seasonality
of varicella which suggests that if exposure to varicella
does boost against zoster then the average period of
boosting is long relative to the epidemic time scale
(1 year).
Hospitalization and inpatient days
The age-specific hospitalization rate, proportion of
hospitalized zoster cases and average number of
inpatient days are very similar between Canada and
the United Kingdom (Table 3). The proportion of
inpatient hospitalizations per zoster case is approxi-
mately 3% in the 0–4 year age group, decreases to 1%
in 5–14 year olds, then increases throughout adult life
to more than 10% in individuals over 65 years (Table
3). Furthermore, the average number of inpatient
days per zoster admission increases with age from
approximately 6 days in 0–4 year olds to 19 days in the
elderly (over 65 years) (Table 3).
DISCUSSION
The overall epidemiology of varicella and zoster (i.e.
age distribution, incidence, seasonality and morbidity)
is similar between Canada and the United Kingdom
and is consistent with studies in other developed
countries [1, 6, 31–39]. Though sentinel reporting may
overestimate the proportion of cases in older age
groups (due to a larger proportion consulting their
physicians), most consultations are for childhood
infection. The age-specific distribution of varicella
cases reported by general practitioners is similar
between the United Kingdom and Canada (around
85% are in children under 15 years) and is comparable
to surveillance data in France (92% of consultations)
and Scotland (79%) [1, 33]. The highest consultation
rate is in 0–4 year olds for Canada and the United
Kingdom. Finally, it should be noted that the overall
consultation rates are slightly higher in the United
Kingdom than in Canada. This is to be expected since
varicella cases reported by general practitioners are
determined by patient consultation patterns, which
partly depend on the primary health care system of
each country.
The shape of the force of infection estimated for
Canada and the United Kingdom (increasing in the
pre-school years, peaking during primary school and
declining thereafter) is consistent with other countries
and with that of other childhood infections such as
measles, mumps and rubella [40, 41]. This suggests
that preschool and school-age mixing is an important
determinant of varicella transmission as with other
childhood infections such as measles and rubella.
The age-specific consultation rate from Canada and
the United Kingdom suggest that varicella has an
annual epidemic cycle with more cases occurring
during spring. Annual periodicity of varicella has also
been observed in France and the United Kingdom [33,
34]. Contrary to Canada, which has one peak (June,
Fig. 2a), the United Kingdom has two peaks of
varicella incidence (middle of March and June, Fig.
2d). This difference in seasonality might be due to the
school calendar. In the United Kingdom, spring
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Table 3. Age specific risk of aricella and herpes zoster hospitalization and aerage length of stay in the UK
(1995}6) and Canada (1979–97)
Age group
Hospitalization
(per 100000 population)*
Hospitalization
(per case, %)
Average length of
stay (days)
UK Canada UK Canada UK Canada
Varicella
0–1 74 71 1–6 1–8 2–6 5–5
2–4 36 40 0–8 0–4 2–9 5–0
5–11 8 11 0–3 0–2 3–4 4–5
12–18 2 2 0–1 0–4 8–4 4–6
19–24 4 2 1–2 0–5 3–2 4–3
25–44 4 3 1–3 1–4 4–9 8–7
45–64 1 1 1–9 1–9 8–0 10–2
65› 1 2 5–5 7–0 16–1 18–0
Herpes zoster
0–4 2 1 4–4 2–2 6–2 5–1
5–14 2 2 0–6 1–4 4–9 4–6
15–44 3 2 1–1 1–0 7–2 8–0
45–64 13 12 2–4 2–8 10–4 11–6
65› 148 86 14–4 10–6 18–9 20–0
* Population estimates were taken from the Office of National Statistics for England and Statistics Canada for Manitoba.
 The proportion of cases hospitalized relates to the number of hospitalizations divided by the estimated number of cases
for the same time period. Cases of varicella were calculated by adjusting the observed number of consultations by the
estimated age specific percent of children with varicella seen by a physician (see methods for values). Zoster consultation rates
were assumed to be reasonable estimates of incidence rates.
vacation lasts at least 2 weeks (twice the duration of
the varicella infectious period) but in Canada it only
lasts a week. Annual periodicity declines with age but
is still apparent in adults less than 45 years of age. This
might indicate a higher degree of mixing between
children under 15 and younger adults (children with
parents) than with adults over 45 (children with
grandparents). On the other hand the lack of
seasonality in adults over 45 could be due to a smaller
number of cases (i.e. lack of power to detect
seasonality) and}or be due to a misclassification of
some zoster cases as varicella.
Because of its high severity [1, 37, 38] most
individuals with zoster are likely to consult a general
practitioner. Zoster consultation rates are thus likely
to be a reasonable estimate of incidence rates. Similar
to other industrialized countries [37, 39], more than
60% of zoster cases in Canada and the United
Kingdom are in adults over 45 years old. The highest
rate of zoster is in 65› year olds [34, 38] and seems to
be increasing in the elderly population. This is at least
partly attributable to the ageing of the population.
Since the rates of reactivation increase with age
especially for those aged 75 and older, an upward shift
in the age distribution of the elderly can increase
zoster rates in over 65 year age group. Indeed, when
Canadian zoster rates are stratified into 65–74 and
75› year age groups the specific rates increase less
over time than the rate for the un-stratified 65› age
group.
Differences in the epidemiology of varicella and
zoster between Canada and the United Kingdom can
provide us with a better understanding of the
dynamics of the varicella zoster virus. Differences in
seasonality between the United Kingdom and Canada
illustrate that contact patterns between school terms
and vacation play an important role in the dynamics
of varicella. Furthermore, an important shift in the
age-specific incidence of infection has been observed
in the United Kingdom. Interestingly, the shift in the
age distribution of consultations in the United
Kingdom coincides with a significant increase in
children attending preschool [1, 42, 43]. Between 1970
and 1992 the number of children attending preschool
has increased from 10 to 50% [1]. In contrast, the
proportion of children attending preschool remained
relatively constant in Canada at 10% between 1979
and 1994 (www.stat.gouv.qc.ca). The dramatic change
in preschool attendance in the United Kingdom, by
increasing the opportunity for effective contact be-
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tween children under 5, might be responsible for such
a shift in the age distribution of varicella [1]. Similar
trends have been observed in the United States [31, 44,
45]. Changes in the consultation patterns of children
and in the age distribution of the population might
also contribute to the shift in the age distribution of
reported varicella cases. It is interesting to note that,
the fall of UK varicella consultation rates in 5–14 year
olds coincides with an increase in zoster in the same
age group. This reduction could be because more
cases of varicella in 0–4 year olds increases the
potential for reactivation during childhood (i.e. 5–14
years), and perhaps a fall in natural boosting of
immunity due to a decline in the incidence of varicella
[6]. The shift in the age at infection in the United
Kingdom and difference in seasonality between the
United Kingdom and Canada indicate that school
and pre-school contact patterns must be carefully
taken into account when assessing the impact of
vaccination.
Hospitalization and inpatient days should reflect
the age-specific severity (morbidity) of disease.
Hospital admission data from Manitoba and England
show a steep increase in both varicella and zoster
hospitalizations and average number of inpatient days
with age. This is consistent with results from the
United States although the age-specific proportion of
cases that result in hospitalization is slightly lower in
the United States [32, 34–36, 46]. Theses dissimilarities
are most likely due to the difference in the structure of
the various health systems. Since, currently, varicella
occurs mainly in children the increase in severity with
age does not lead to a high number of varicella related
hospital days. However, mass immunization results in
an increase in the average age at infection in those
who are not immunized. Therefore, there is a danger
that mass immunization can lead to an increase in
hospitalization and inpatient days. Such perverse
outcomes from mass infant vaccination has been
observed for rubella in Greece [47]. However, mod-
elling work using the Manitoba age-specific
hospitalization and inpatient day data suggests that,
regardless of vaccine coverage, infant vaccination is
unlikely to shift the average age at infection to such an
extent that the total morbidity will be worse than the
pre-vaccination state [16]. Although immunization is
unlikely to cause more harm than good, any increase
in the number of adult cases would deleteriously affect
the cost-effectiveness of varicella vaccination.
Zoster is considered to be much more severe than
varicella. Contrary to general belief, age-specific
severity, as measured by the age-specific proportion of
hospitalization per case and inpatient days, is only
slightly higher for zoster than varicella (Table 3).
However, the overall burden of disease is considerably
higher for zoster because over 80% of cases occur in
adults (less than 15% for varicella). The total number
of inpatient days attributable to zoster in England for
1995}6 was 61937 days compared to 10992 days for
varicella. In Manitoba the average number of
inpatient days per year between 1979 and 1997 was
2815 days for zoster compared to 425 days for
varicella. This corresponds to a 6- to 7-fold difference
between the number of annual zoster and varicella
inpatient days. Furthermore, since the validity of
diagnostic codes for varicella appears to decrease
markedly after age 50 years [35] the relative con-
tribution of varicella to VZV hospitalizations might
be overestimated among older individuals.
Zoster may occur more frequently in adults who
have not been boosted by varicella contacts (6). A
reduction of varicella incidence after mass immu-
nization could lead to an increase in the incidence of
zoster. This could have a major impact on the overall
effectiveness and cost-effectiveness of varicella vac-
cination [16]. Furthermore, the VZV vaccine is the
first of its kind that actually induces latency (reacti-
vations may be due to the vaccine). Surveillance of
zoster incidence should be a priority in countries
where varicella immunization is underway. The
Manitoba and England and Wales surveillance
systems would allow a detailed surveillance of both
zoster and varicella should mass immunization take
place.
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